This review synthesizes current biochemical and structural insights into HIV-1 entry, with emphasis on envelope conformational dynamics, receptor and co-receptor interactions, membrane fusion mechanisms, and host determinants that regulate entry efficiency and tropism.
Abstract
The global HIV/AIDS pandemic continues to pose a major public health challenge, underscoring the need for improved mechanistic understanding of viral infection and therapeutic intervention. HIV-1 infection is initiated by a highly orchestrated entry process that represents the first and most decisive determinant of productive infection. This process begins with binding of the viral envelope glycoprotein gp120 to the CD4 receptor, followed by engagement of the chemokine co-receptors CCR5 or CXCR4, triggering conformational rearrangements that activate gp41-mediated membrane fusion. This review synthesizes current biochemical and structural insights into HIV-1 entry, with emphasis on envelope conformational dynamics, receptor and co-receptor interactions, membrane fusion mechanisms, and host determinants that regulate entry efficiency and tropism. We further examine how these early events shape subsequent post-entry processes, including capsid stability and intracellular trafficking, that are essential for productive infection. Therapeutic strategies targeting viral entry, including attachment inhibitors, fusion inhibitors, co-receptor antagonists, and broadly neutralizing antibodies are critically discussed, alongside emerging challenges such as resistance and viral heterogeneity. Finally, we highlight key knowledge gaps in entry biology, including alternative entry routes and cell-to-cell transmission, and discuss how addressing these may inform next-generation antiviral and preventative strategies.
This review highlights promising protein-based HIV entry inhibitors that have demonstrated efficacy in preclinical studies, and discusses ongoing efforts to optimize their valency, avidity, specificity, serum half-life, effector functions, and production platforms to improve their therapeutic potential and economic fea...
Rashmi Kumariya, Carole A. Bewley· Biomolecules· 0 citations
Human Immunodeficiency Virus type-1 (HIV-1) infects CD4+ T cells and remains a global pandemic due to our incomplete understanding of the molecular mechanisms underlying its highly coordinated and regulated assembly process and the strategies it uses for immune evasion. For HIV-1 to produce infectious particles, the vi...
The molecular mechanisms through which EVs have been proposed to contribute to HIV infection are examined, focusing on host–virus interactions, immune regulation, chronic inflammation, and viral latency.
Flora Salzano, Nicoletta Capuano, F. Giordano et al.· FEMS Microbiology Reviews· 0 citations
ABSTRACT African swine fever (ASF), caused by the African swine fever virus (ASFV), remains one of the most devastating transboundary animal diseases worldwide, with case fatality rates reaching up to 100% in acute infections. Viral entry represents the first essential step in infection and is an ideal target for the d...
Jia-Qi Li, Chuan-Xia Liu, Wei-Tao Huang et al.· Journal of Virology· 0 citations
The combination knockout of CCR5, MOGS, and viral sequences profoundly reduces HIV-1 replication in an ex vivo cellular model, that is, HIV-1-infected peripheral blood mononuclear human cells, thus offering a pathway to launch further preclinical studies.
Z. Safaei, Anna Bellizzi, Hong Liu et al.· Human Gene Therapy· 0 citations
HIV-1 fusion with host cells is initiated upon engagement of the viral envelope (Env) protein by its receptors and co-receptors. Receptor-induced conformational changes in the Env ectodomain expose the fusion machinery and position the HIV-1 fusion peptide for release and transit to the host membrane. However, no allos...
Do N. Hung, Muralikrishna Lella, D. Fulmali et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.